Overview of Glp 1 Receptor Agonists And Kidney Protection

The weight-loss effects of GLP -1RAs prompted subsequent studies to investigate the potential cardiovascular benefits of these agents in persons with obesity and without diabetes. Analysis of secondary kidney endpoints from the above trials provided the first evidence that GLP -1RAs may also afford kidney protection .

Glucagon-like peptide-1 receptor ( GLP -1R) agonists are a new class of anti-hyperglycemic drugs which have been demonstrated to prevent the onset of macroalbuminuria and reduce the decline of GFR in diabetic patients.
Key Details About Glp 1 Receptor Agonists And Kidney Protection

Although further research is needed to define their role in nondiabetic chronic kidney disease, the growing body of evidence highlights GLP-1 receptor agonists as important agents in kidney protection .
Clinicians may consider GLP -1RAs as a dual-purpose therapeutic agent for both cardiovascular and renal protection . Findings support the design of future trials focusing on GLP -1RAs in non-diabetic chronic kidney disease populations. Results may influence clinical guidelines to expand the indications of GLP -1RAs beyond glycaemic control in diabetes.

Useful Notes on Glp 1 Receptor Agonists And Kidney Protection
Third, what is the mechanism of kidney protection with GLP-1 receptor agonists ? Although mediation analyses previously suggested changes in glycemia and blood pressure contributed moderately to kidney benefits, direct effects remain to be identified.
Glucagon-like peptide-1 ( GLP-1 ) receptor agonists are incretin-based therapies initially developed for the management of type 2 diabetes. In addition to improving glycemic control and promoting weight loss, these agents have demonstrated cardiovascular and potential renal benefits. This review explores the mechanisms by which GLP-1 receptor agonists may exert renoprotective effects, including ...

Overview of Glp 1 Receptor Agonists And Kidney Protection
Cases A. Glucagon-like peptide 1 ( GLP-1 ) receptor agonists in the management of the patient with type 2diabetes mellitus and chronic kidney disease: an approach for the nephrologist.
About GLP-1 Receptor Agonists ( GLP-1 RAs) GLP-1 receptor agonists ( GLP-1 RAs) are a type of prescription medicine commonly recommended for people with type 2 diabetes and /or obesity. Combined with healthy eating habits and physical activity, GLP-1 RAs can help you keep your blood sugar levels in the goal range and lose weight (if needed).

Key Details About Glp 1 Receptor Agonists And Kidney Protection
This Review appraises the current status of GLP-1 peptide and its receptor agonists and focuses on the preclinical as well as recent seminal clinical findings defining the kidney benefits conferred by GLP-1 receptor agonist treatment in people living with type 2 diabetes and obesity. Introduction




The GLP-1 receptor agonist semaglutide reduces risks of kidney function loss, kidney failure, cardiovascular events, cardiovascular death and all-cause mortality in people with chronic kidney ...